CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$78.94−5.84 (-6.89%)
Close on Nov 17, 2026Market cap $7.00BP/E –Yield –
CG Oncology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
CG Oncology's operating cash flow for the twelve months ending Sep 30, 2026 was -$187.28M. For fiscal 2025 it was -$132.35M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$132.35M | – |
| FY2024 | Dec 31, 2024 | -$78.71M | – |
| FY2023 | Dec 31, 2023 | -$45.68M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$47.71M | – |
| Q2 FY2026 | Jun 30, 2026 | -$46.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$56.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$26.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.99M | – |
See a number that looks wrong?